D-0552-2023 Class II Ongoing
FDA drug recall D-0552-2023 was initiated by Northwind Pharmaceuticals LLC on Mar 16, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is ongoing. Affected quantity: a) 198 bottles; b) 22 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- May 3, 2023
- Initiation Date
- Mar 16, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 198 bottles; b) 22 bottles
Product description
Glimepiride Tablets, USP 4mg, packaged in a) 30-count bottles (NDC 51655-120-52), and b) 90-count bottles (NDC 51655-120-26), Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203.
Reason for recall
CGMP Deviations
Distribution pattern
Nationwide with the United States
Code information
a) Lot #: F105692201, Exp. Date 09/30/2024; F105692203, Exp. Date 02/28/2025 b) Lot #: F105692202, Exp. Date 02/28/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0552-2023
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026